Participants described earlier phenotyping, closer tracking of steroid exposure, and recognizing gradual gains on biologic therapy.
|Articles|September 16, 2008
- March31 2003
- Volume 10
- Issue 6
A WILL ONLINE
Author(s)Michael Sheehan
Advertisement
Physician's Money Digest
Several surveys have confirmed that morethan 50% of doctors do not evenhave the most basic of estate planningdocuments—a will. Many busyphysicians cite time constraints asan excuse for a lack of estate planningpreparation; however, the Website www.legaldocs.com lets youprepare many customized legal documents(including wills) directlyonline and at very reasonable prices.Choose from any of the documentsoffered, answer the questions, clickthe "submit" button, and the finisheddocument is ready to downloador print. Many documents arefree or low-cost. If you create a willand have it signed in the presence of2 witnesses (nonheirs), it is considereda legal document.
Articles in this issue
about 18 years ago
WAR AND WALL STREETabout 18 years ago
THE 529 FACTSabout 18 years ago
A WILL THAT WORKSabout 18 years ago
WALL STREET WOESabout 18 years ago
FINANCIAL PLANNING KEYabout 18 years ago
MIXED SIGNALSabout 18 years ago
PAPERWORK REDUCTIONabout 18 years ago
SHRINKING GIFTSabout 18 years ago
Medicare Cuts Deniedabout 18 years ago
DID YOU KNOW…Advertisement
Related to this article
Interim IMAgINATION data show the once-monthly factor B antisense therapy sefaxersen reduced proteinuria by 43.1% vs placebo at week 37 in IgA nephropathy.
Interim RAINIER data show povetacicept reduced proteinuria by 52.0% and resolved hematuria in 85% of patients at week 36, ahead of a November PDUFA date.
Interim I CAN data show ravulizumab reduced proteinuria by 43.4% vs placebo at week 34, supporting its FDA accelerated approval in IgA nephropathy.
Lorundrostat cut systolic BP by 9.6 mm Hg and UACR by 52.2% vs placebo in participants with CKD and uncontrolled hypertension in Launch-HTN.
The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
Final TELIGAN data show telitacicept cut confirmed 30% eGFR decline by 89% and reduced proteinuria by 60.7% vs placebo over 2 years in IgA nephropathy.
Participants described how payer requirements and documentation of steroid exposure shape biologic access.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women
3
Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D
4
TELIGAN: Telitacicept Preserves eGFR Through 2 Years in IgA Nephropathy
5